Abiopharma

🔍 Leach Jacob Steven (Director)

Company: DEXCOM INC (DXCM)

Report Date: 2026-03-08

Detailed Transactions and Holdings:

• Acquired 104,516 shares of Common Stock (Direct)
  Date: 2026-03-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 441,567.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 19,757 shares of Common Stock at $68.1 per share (Direct)
  Date: 2026-03-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 421,810.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-08 | Code: H | nature_of_ownership: Family Holdings | shares_owned_after: 47,296.00 | Footnotes: F4

Footnotes:

• F1: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.
• F2: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.
• F3: Included in this number are 148,536 unvested RSUs, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
• F4: Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee.